<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">Tumor lysis syndrome</z:e> is a life-threatening complication of chemotherapy for patients with <z:hpo ids='HP_0001909'>leukemia</z:hpo> and large <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with a high proliferative index, such as Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The syndrome is characterized by <z:hpo ids='HP_0002153'>hyperkalemia</z:hpo>, <z:hpo ids='HP_0002905'>hyperphosphatemia</z:hpo>, <z:hpo ids='HP_0002901'>hypocalcemia</z:hpo>, and <z:hpo ids='HP_0002149'>hyperuricemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The standard of care for <z:hpo ids='HP_0002149'>hyperuricemia</z:hpo> consists of hydration with or without alkalinization and administration of <z:chebi fb="0" ids="40279">allopurinol</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>When treated in this manner, patients often experience persistent <z:hpo ids='HP_0002149'>hyperuricemia</z:hpo> that lasts several days after the start of <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> therapy; sometimes they develop <z:chebi fb="3" ids="27226">uric acid</z:chebi> <z:hpo ids='HP_0000112'>nephropathy</z:hpo> as a consequence </plain></SENT>
<SENT sid="4" pm="."><plain>Rasburicase, a recombinant urate oxidase enzyme, quickly removes large amounts of <z:chebi fb="3" ids="27226">uric acid</z:chebi> from plasma </plain></SENT>
<SENT sid="5" pm="."><plain>The drug is approved by the United States Food and Drug Administration for management of elevated plasma <z:chebi fb="3" ids="27226">uric acid</z:chebi> levels in pediatric patients with <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, or <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> who are receiving chemotherapy </plain></SENT>
<SENT sid="6" pm="."><plain>We undertook a retrospective review of adult patients treated with a single dose of rasburicase 6 mg for <z:hpo ids='HP_0002149'>hyperuricemia</z:hpo> associated with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Ten patients received one 6-mg dose of rasburicase, and one patient received two 6-mg doses as an adjuvant therapy to normalize <z:chebi fb="3" ids="27226">uric acid</z:chebi> levels </plain></SENT>
<SENT sid="8" pm="."><plain>In most of the patients, a single 6-mg dose of rasburicase was effective in correcting <z:chebi fb="3" ids="27226">uric acid</z:chebi> levels in the typical time between diagnosis and start of <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> therapy </plain></SENT>
</text></document>